Oxygen Double Bonded And Nitrogen Bonded Directly To The Same Carbon Patents (Class 536/53)
  • Patent number: 11890293
    Abstract: A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2?-fucosyllactose (2?-FL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3?,6-disialyllacto-N-tetraose (DSLNT), 6?-sialyllactose (6?-SL), and 3?-sialyllactose (3?-SL); and mixtures thereof.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: February 6, 2024
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, Emma Elison
  • Patent number: 11883421
    Abstract: The present invention relates to functionalized saccharides anti-inflammatory agents which acts upon inflammatory mechanisms in mammals, in particular anti-inflammatory agents which act upon the expression of at least one cytokine by suppressing or inhibiting the expression of the at least one cytokine wherein said cytokine is selected from the group consisting of pro-inflammatory cytokines, anti-inflammatory cytokines and chemokines.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 30, 2024
    Assignee: HUVEPHARMA
    Inventors: Spas Petkov, Veerle Hautekiet
  • Patent number: 11834406
    Abstract: A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a Formula (I), wherein T, L, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R1, R12, and R13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: December 5, 2023
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventors: R. Yongxin Zhao, Yue Zhang, Yourang Ma
  • Patent number: 11801329
    Abstract: The disclosure herein relates to photoinitiated dermal fillers, hyaluronic acid-rhCollagen double crosslinked dermal fillers and hyaluronic acid-rhCollagen semi interpenetrated network, each comprising plant-derived human collagen, as well as methods of using the same.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: October 31, 2023
    Assignee: CollPlant Ltd.
    Inventors: Oded Shoseyov, Nadav Orr, Jasmine Seror Maknouz, Revital Zarka
  • Patent number: 11766393
    Abstract: A skin care composition comprising low molecular weight acetylated hyaluronic acid or its sodium salt having a weight average molecular weight less than 50 kDa, and a degree of acetylation of at least 3.6 is useful in the treatment of the visible effects of age on human skin.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: September 26, 2023
    Assignee: GIVAUDAN SA
    Inventors: Martin Lovchik, Gerhard Brunner, Romain Reynaud, Amandine Scandolera
  • Patent number: 11707419
    Abstract: A first problem is to provide a novel technique for forming hyaluronan into particles. Further, a second problem is to provide a novel technique suitable for production of a composite particle containing an anionic polymer and a peptide. Means for solving the first problem is a composite particle containing an anionic polymer, and a cationic polymer (except for chitosan) having a degree of cationization of 0.2 or more. Means for solving the second problem is to mix an anionic polymer and a peptide in an aqueous solvent having a pH of 5 or less.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: July 25, 2023
    Assignee: POLA CHEMICAL INDUSTRIES, INC.
    Inventor: Ryota Hayashi
  • Patent number: 11708461
    Abstract: A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: July 25, 2023
    Assignee: Galderma Holding SA
    Inventors: Johan Olsson, Craig Steven Harris
  • Patent number: 11643478
    Abstract: Provided is a low-molecular-weight holothurian glycosarninoglycan, with the constituent units thereof being a glucuronic acid group, an N-acetaminogalactose group and a fucose group, and a sulfate ester group or acetyl ester group thereof. Glucuronic acid and N-acetaminogalactose are interconnected via ?(1-3) and ?(1-4) glucosidic bonds to form a backbone of a disaccharide repeating structural unit, and a fucose group is connected to the backbone as a side chain. On a molar ratio basis, the ratio of the glucuronic acid group:the N-acetaminogalactose group:the fucose group is 1:(0.8-1.2):(0.6-1.2). In the structure of the low-molecular-weight holothurian glycosaminoglycan, 10-30% of glucuronic acid groups are modified, on the 2-position, with a sulfate ester group, and the rest are hydroxyl groups; and a proportion of 10-30% of fucose groups is modified, on the 2-position, with an acetyl ester group, and the rest are hydroxyl or sulfate ester groups.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 9, 2023
    Inventors: Yongsheng Jin, Xiujuan Ding, Wu Chen, Xiaoming Li, Junting Sun, Yihao Zhu, Xiaohua Lu, Caijuan Jin, Hua Zhou, Ningxia Wang, Yongbao Li, Qiaoyun Zhou, Jiangen Qian, Xi Chong, Yiming Yao, Yi Jiang
  • Patent number: 11541147
    Abstract: Provided are a hyaluronic acid composition having excellent viscoelasticity and being easily injectable, and a preparation method thereof.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: January 3, 2023
    Assignee: CG BIO CO., LTD.
    Inventors: Su Hyun Jung, Jun Hyuk Seo, Hyun Seung Ryu, Hak Su Jang
  • Patent number: 11524079
    Abstract: Disclosed herein is a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. Also disclosed herein are the uses of the hyaluronan conjugate in treating or preventing neurodegenerative diseases.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: December 13, 2022
    Assignee: AIHOL CORPORATION
    Inventors: Szu-Yuan Lee, Ping-Shan Lai, Chih-An Lin
  • Patent number: 11458151
    Abstract: Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 4, 2022
    Assignee: INIMMUNE CORPORATION
    Inventors: Helene Bazin-Lee, George Ettenger, Juhienah Khalaf, Kendal T. Ryter
  • Patent number: 11359030
    Abstract: The present invention relates to a method for preparing low molecular weight hyaluronic acid having a molecular weight of 100,000 to 200,000 daltons, the method comprising heating treatment, in the pH range 2.5 to 3.5, for an aqueous solution that contains hyaluronic acid having a molecular weight of 500,000 daltons or greater.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 14, 2022
    Assignee: YOUREH CO., LTD.
    Inventor: Hyang Mae Um
  • Patent number: 11296324
    Abstract: The present disclosure provides a rotaxane polymer binder containing a polymer based on a rotaxane structure. The polymer binder may further contain a polymer cross-linked with a polar polymer. The polar polymer may be a polymer containing the element F, O or N in a functional group and having high polarity. In addition, the present disclosure provides an electrode containing the rotaxane polymer binder as a binder for a lithium secondary battery, and a secondary battery containing the electrode.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: April 5, 2022
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jang Wook Choi, Ali Coskun, Sung Hun Choi, Tae Woo Kwon
  • Patent number: 11186652
    Abstract: A method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells is provided, said method comprising a step of extracting LPS from the gram negative bacterial cell in a LPS extraction solution comprising a salt, water, an alcohol, and a further organic solvent. Compositions and uses of the extracted LPS are also provided.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 30, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Jeffrey A. Kern, Chad Farrenburg
  • Patent number: 10988508
    Abstract: The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and ethyl azide linker prepared from 2-azido-ethanol, and Za is selected from the group consisting of OH, an ethylene diamine coupled fluorophore, a peptide and a peptide with an ethylene diamine coupled fluorophore, wherein the peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide and a pentapeptide. Also provided are methods for synthesizing NAM derivatives and methods for modulating Nod2 in cells, modifying bacterial cell wall or modulating innate immune response by a subject to bacterial cells upon exposure to NAM derivatives.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 27, 2021
    Assignee: University of Delaware
    Inventors: Catherine Leimkuhler Grimes, James E. Melnyk, Kristen E. Demeester, Hai Liang
  • Patent number: 10980860
    Abstract: The present invention relates to a polymeric prodrug for use in the treatment, prevention and/or diagnosis a disease of the joint and pharmaceutical compositions and medical devices comprising said polymeric prodrugs.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: April 20, 2021
    Assignee: Ascendis Pharma A/S
    Inventors: Dirk Vetter, Ulrich Hersel, Kennett Sprogøe, Nora Kaluza, Oliver Keil, Guillaume Maitro, Harald Rau
  • Patent number: 10836834
    Abstract: Provided is a complex obtained by reacting a polymer compound derivative obtained by modifying part of the hydroxy groups or amino groups of a polymer compound having the hydroxy groups or amino groups with a compound represented by the following general formula (I) with one or more kinds of compounds represented by the following general formulae (II) to (V): (I) A-X—Si(Y)nR3-n; (II) M(OR1)nR24-n; (III) Al(OR1)pR23-p; (IV) Mg(OR1)qR22-q; and (V) [Si(OR3)nR43-n]—(X)—[Si(OR5)nR63-n].
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 17, 2020
    Assignee: DAICEL CORPORATION
    Inventors: Yoshio Okamoto, Chiyo Yamamoto, Tomoyuki Ikai, Masami Kamigaito
  • Patent number: 10745432
    Abstract: An object of the present invention is to provide a crystal of 6?-sialyllactose (hereinafter, referred to as 6SL) sodium salt, which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a production process thereof. The present invention relates to a crystal of 6SL sodium salt and a process for producing the crystal.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 18, 2020
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Masahiro Abe, Tomoya Yokoi, Sotaro Sanpei, Kazunari Fukumoto, Hiroshi Nagano
  • Patent number: 10640578
    Abstract: The present invention generally relates to a modified hyaluronic acid (HA) and to a method for making same, more specifically to a (poly)glycerol-modified HA derivative prepared by grafting glycidol to HA. The present invention also relates to the use of the HA derivative for preparing a dermal filler composition, a hydrogel comprising cross-linked HA and the (poly)glycerol-modified HA derivative, and a method for preparing said hydrogel. Furthermore, the present invention relates to the use of the hydrogel as a cosmetic and/or aesthetic product, in particular as a dermal filler for tissue filling, replacing and/or augmenting.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: May 5, 2020
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Andreas Krause, Alexander Linko, Franck Villain
  • Patent number: 10463595
    Abstract: The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 5, 2019
    Assignee: ALLERGAN HOLDINGS FRANCE S.A.S.
    Inventors: Geoffrey C. Gurtner, Kenneth N. Horne, Jayakumar Rajadas
  • Patent number: 10024795
    Abstract: Provided is a method of monitoring a vesicle in a sample, including contacting a vesicle in a sample with a membrane permeable marker that is converted into a detectable marker in the vesicle, measuring a signal of the detectable marker, and monitoring the vesicle based on the measured signal.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 17, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyun-ju Kang, Ye-ryoung Yong, Myo-yong Lee
  • Patent number: 9717754
    Abstract: The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: August 1, 2017
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Maya Margalit, Ari Zimran
  • Patent number: 9718947
    Abstract: A process for the preparation of a chondroitin sulphate salt with an average molecular weight (Mw) of 10-30 kDa via chemical sulphation of an unsulphated chondroitin backbone is provided. The unsulphated chondroitin can be obtained by acid hydrolysis of a capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4 or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: August 1, 2017
    Assignee: Gnosis S.p.A.
    Inventors: Davide Bianchi, Marco Valetti, Paola Bazza, Nicolò Miraglia, Ermanno Valoti
  • Patent number: 9597675
    Abstract: An oxidation catalyst includes a support including particles of an alkaline earth salt, and first particles including a palladium compound on the support. The oxidation catalyst can also include precious metal group (PMG) metal particles in addition to the first particles intermixed together on the support. A gas permeable polymer that provides a continuous phase can completely encapsulate the particles and the support. The oxidation catalyst may be used as a gas sensor, where the first particles are chemochromic particles.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: March 21, 2017
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Nahid Mohajeri
  • Patent number: 9585987
    Abstract: A composition, which upon activation, spontaneously forms a cross-linked hydrogel in aqueous liquid, includes: a) a formulation containing a hyluronan (HA-formulation) which includes a hyaluronan backbone (HA backbone) and a plurality of a reactive substituent group (reactive HA substituent) which i) is directly attached to the HA backbone, and ii) exhibits the reactive HA-group, and b) a formulation of a homo-multifunctional cross-linking reagent (CLR-formulation) exhibiting a plurality of a reactive group (reactive CLR-group). The two reactive groups are selected as a pair of counterparts that mutually and selectively react with each other to form a linkage structure. The hydrogel contains a cross-linking structure which a) is attached to the hyaluronan via two or more of the linkage structure and is defined by the reagent. The cross-linking structure exhibits a plurality of hydroxyl groups. The composition can be used in vivo or ex vivo as a support matrix.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: March 7, 2017
    Assignee: PVAC MEDICAL TECHNOLOGIES LTD
    Inventors: Kristoffer Bergman, Tim Bowden, Thomas Engstrand, Jons Hilborn, Dmitri Ossipov
  • Patent number: 9567447
    Abstract: An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: February 14, 2017
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Susan P. James, Min Zhang, Guy Beauregard
  • Patent number: 9554987
    Abstract: The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 31, 2017
    Assignee: ULTRAGENYX PHARMACEUTICAL INC.
    Inventor: Emil Kakkis
  • Patent number: 9556467
    Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 31, 2017
    Assignee: Garnet Bio Therapeutics, Inc.
    Inventors: Vanessa Ragaglia, Vandana Madanlal Sharma
  • Patent number: 9533077
    Abstract: The present disclosure provides, inter alia, a method of producing an outer layer material for forming into a structure and that comprises an entanglement having a hydrophobic polymer host and a hydrophilic guest, including in one embodiment the steps of: intermingling cloaked hydrophilic guest complexes with the hydrophobic host; crosslinking molecules of the guest with the guest; and performing a hydrolysis reaction.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 3, 2017
    Assignee: Colorado State University Research Foundation
    Inventors: Susan P. James, Min Zhang, Guy Beauregard, Rachael Kurkowski Oldinski
  • Patent number: 9511015
    Abstract: The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: December 6, 2016
    Assignee: ULTRAGENYX PHARMACEUTICAL INC.
    Inventor: Emil Kakkis
  • Patent number: 9371352
    Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 21, 2016
    Assignees: VACCINEX, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Steven A. Porcelli, Maurice Zauderer
  • Patent number: 9161945
    Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: October 20, 2015
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Kakinuma, Yohei Kobashi, Tomomichi Chonan, Fumiyasu Shiozawa, Yuki Iwata, Takahiro Oi, Kenichi Kawabe
  • Patent number: 9107882
    Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: August 18, 2015
    Assignee: PERNIX THERAPEUTICS HOLDINGS, INC.
    Inventor: Robert Lewis
  • Patent number: 9067960
    Abstract: Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: June 30, 2015
    Assignee: The Johns Hopkins University
    Inventors: Kevin J. Yarema, Udayanath Aich, Christopher T. Campbell, Srinivasa-Gopalan Sampathkumar, Sean S. Choi, Michael A. Meledeo, Christopher Weier
  • Patent number: 9051592
    Abstract: The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 9, 2015
    Assignee: Garnet Biotherapeutics, Inc.
    Inventors: Vanessa Ragaglia, Vandana Madanlal Sharma
  • Publication number: 20150148310
    Abstract: The present invention generally relates to deuterium-enriched hyaluronan, d-HA, compositions containing the same, methods of using the same, and methods for making the same.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventor: Glenn Prestwich
  • Patent number: 9034844
    Abstract: The present invention relates to a process of synthesis of ?-sialyl oligosaccharides and in particular of 6?-sialyllactose and its salts comprising a step of coupling by Koenigs-Knorr reaction under conditions that allow its use on an industrial scale.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: May 19, 2015
    Assignee: INALCO S.P.A.
    Inventors: Giancarlo Tamerlani, Ilaria Lombardi, Debora Bartalucci, Andrea Danesi, Liana Salsini, Marco Manoni, Giovanni Cipolletti
  • Publication number: 20150126468
    Abstract: A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.
    Type: Application
    Filed: August 22, 2011
    Publication date: May 7, 2015
    Inventors: Sunil Shaunak, Ian Alfred Teo
  • Publication number: 20150126727
    Abstract: The present invention provides a method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells comprising the step: extracting LPS from the cell culture in a composition (LPS extraction composition) comprising water, an alcohol and a further organic solvent.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Philippe CHARLES, Geoffroy GELDHOF, Vincent MANCUSO
  • Patent number: 9023830
    Abstract: There is disclosed a cosmetic comprises a sugar compound obtained by reacting a hydroxyl group of a saccharide, an isocyanate group-containing organopolysiloxane represented by the following general formula (1), and an isocyanate group-containing organic compound represented by the following general formula (2). As a result, there is provided a cosmetic excellent in cosmetic sustainability and storage stability that can improve such undesirable feelings of use as insufficient spreadability and stickiness, improve the solubility to not only a non-polar oil such as a silicone oil and a light liquid paraffin, but also a polar oil such as a UV-absorber, an ester oil, and a natural animal and vegetable oil, provides non-stickiness with a cosmetic containing the polar oil, and prevent adhesion of the cosmetic to clothes (secondary adhesion).
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: May 5, 2015
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventor: Masanao Kamei
  • Publication number: 20150119360
    Abstract: The present invention provides a growth promoting composition capable of promoting growth of a microorganism belonging to the genus Bifidobacterium living in the intestine of mammals such as human and the like. According to the present invention, a composition for promoting growth of a microorganism belonging to the genus Bifidobacterium, comprising one or more kinds selected from the group consisting of Lacto-N-tetraose, Lacto-N-neotetraose and derivatives thereof can be provided. The aforementioned growth promoting composition is suitable for promoting growth of the aforementioned microorganism in the intestine by oral administration to, particularly, a human adult.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 30, 2015
    Inventors: Kenji Yamamoto, Satoshi Koizumi
  • Publication number: 20150119553
    Abstract: Compounds are disclosed that are useful for noninvasive imaging in the near-infrared spectral range.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 30, 2015
    Inventors: Xinshe Xu, Daniel R. Draney, Lael Cheung
  • Publication number: 20150118322
    Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 30, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Ya-Chin LO, Hsiang-Fa LIANG, Ming-Cheng WEI, Maggie J.M. LU, Min-Ying LIN, Chih-Peng LIU, Chun-MIN LIU, Hsiang-Wen TSENG, Tse-Min TENG, Jui-Hsiang CHEN, Yi-Man CHOU, Yi-Ting HSIEH, Chia-Mu TU
  • Publication number: 20150119354
    Abstract: The present invention provides compounds of Formula (I); or a pharmaceutically acceptable form thereof; wherein R1,R2,R3,R6,R7,R12,Ra, and Rb are as defined herein, and G is a group of Formula (a), (b), or (c): Formula (II), wherein X1; X2, X3, X4, X5, X6, X7, Y, RC, Rd, Rz, a, d, e, x, n, and m are as defined herein. The present invention further provides pharmaceutical compositions comprising a compound of Formula (I), kits comprising such compositions, methods of use and treatment, and preparative methods.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Inventors: Daniel Evan Kahne, Suzanne Walker Kahne, Hirokazu Tsukamoto
  • Publication number: 20150119567
    Abstract: This invention provides low molecular weight lipid-GAG and phospholipids-GAG conjugates and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 30, 2015
    Inventors: SAUL YEDGAR, YUVAL COHEN, JOSEPH V BONDI
  • Publication number: 20150104509
    Abstract: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying to a mucosal surface or a tooth or orthodontic brace of a patient in need thereof an adhering troche comprising at least 5 mg hyaluronan.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventor: Jeffrey Haley
  • Publication number: 20150105337
    Abstract: The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 16, 2015
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Elizabeth Marie Nolan, Tengfei Zheng, Phoom Chairatana
  • Publication number: 20150104643
    Abstract: The invention relates to a crosslinked hyaluronan derivative in the form of a hydrogel or microfibers, and to a method of preparation thereof, consisting in a C—C coupling reaction. The C—C coupling reaction is performed via reaction of a hyaluronan derivative carrying a terminal aryl-halide and/or aryl-borate group, and a hyaluronan derivative carrying an alkenyl or alkynyl group, in water, phosphates buffer or a mixture of an organic acid and an alcohol, and in the presence of a palladium active catalyst. The palladium active catalyst may be e.g. a complex of palladium (II) acetate and an inorganic or organic base, or a complex of palladium (II) and 2-amino-4,6-dihydroxypyrimidine.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 16, 2015
    Inventors: Gloria Huerta-Angeles, Zuzana Jouklova, Eva Prikopova, Vladimir Velebny
  • Publication number: 20150094280
    Abstract: The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 10, 2014
    Publication date: April 2, 2015
    Applicant: SEIKAGAKU CORPORATION
    Inventor: Kenji MIYAMOTO
  • Patent number: 8993536
    Abstract: A low-molecular-weight polysulfated hyaluronic acid derivative useful for treatment of an allergic disease. An agent for treatment of an allergic disease selected from pollinosis, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, and asthma, represented by the following general formula (IA) or (IB); wherein n represents a number of 0 to 15; R's each independently represent a hydrogen atom or an SO3H group etc.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: March 31, 2015
    Assignees: Otsuka Chemical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazuaki Kakehi, Hiroaki Asai, Naohiro Hayashi, Satoshi Shimizu, Fumitaka Goto, Yasuo Koga, Takahiro Tomoyasu, Takao Taki, Yusuke Kato, Satoru Nakazato, Junji Takaba, Atsushi Azuma, Wakako Hirano, Kazunari Izumi, Minoru Kashimoto, Yoko Sakamoto, Takashi Hayashi, Masaru Nishida